Finanzen von Pharming Group NV (PHAR)PHARPharming Group NV

In the context of the broader market, PHAR competes directly with industry leaders such as ZVRA and AVTX. With a market capitalization of $755.20M, it holds a leading position in the sector. When comparing efficiency, PHAR's gross margin of N/A stands against ZVRA's 95.36% and AVTX's N/A. Such benchmarking helps identify whether Pharming Group N.V. is trading at a premium or discount relative to its financial performance.

Pharming has a current P/E ratio of 43.02 and a forward P/E of 212.77, indicating potential overvaluation. The company reported a significant earnings surprise of -90% in its last earnings report, with EPS of 0.02 compared to an estimate of 0.20, which raises concerns about its financial health.